The study identifies a new role of gelsolin “Inflammatory Regulator” BioAegis that is relevant to a number of inflammatory diseases

  • Gelsolin alleviates vascular damage by preventing the release of IL-1β microparticles after high-pressure trauma and decompression.
  • Gelsolin is not immunosuppressive, unlike current treatments to calm inflammatory cytokines.

MORRISTOWN, NJ, April 8, 2021 (GLOBE NEWSWIRE) – BioAegis Therapeutics Inc., a clinical phase, a private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced the publication of a new study entitled “Plasma gelsolin modulates the production and fate of IL-1β-containing microparticles after exposure to high pressure and decompression in the Journal of Applied Physiology. The research was conducted at the University of Maryland School of Medicine.

Inflammation causes a decrease in gelsolin and an increase in microparticles carrying Interleukin-1β
Although human subjects were found to show a moderate decline in gelsolin levels when exposed to high pressure, a deep decline after decompression, in a condition known as decompression sickness, was measured. These changes occurred concurrently with elevations in circulating microparticles carrying interleukin -1β.

  • Interleukin- is an inflammatory cytokine. Increased levels of this cytokine are observed in cytokine storms and a number of inflammatory diseases.
  • Microparticles small vesicles are expelled from cells circulating in the blood and allow communication between cell types in the body.

Human blood neutrophils respond to pressure by releasing microparticles containing interleukin-1β. This release was inhibited in the presence of recombinant human plasma gelsolin (rhu-pGSN).

Similarly, in a mouse model of pressure and decompression, microparticles initiated a systemic inflammatory process associated with neutrophil activation and activation of the NLRP3 inflammation responsible for producing mature interleukin (IL) -1β, the primary factor causing diffuse vascular damage in this model. This inflammatory response depletes gelsolin and results in vascular damage measured in muscle and brain. Rhu-pGSN supplementation alleviates the observed vascular pathology. Gelsolin is not immunosuppressive, unlike current treatments to calm inflammatory cytokines.

Gelsolin supplementation may prevent or reverse interleukin-1Damage to blood vessels caused by β in inflammatory diseases
The study suggests that microparticles play an important role in targeting interleukin-1β to the endothelial mucosa of blood vessels. “Our results suggest that the addition of rhu-pGSN may prevent or reverse decompression sickness by reducing inflammatory microparticles.” This represents a new action for rhu-pGSN that may be relevant to a wide range of inflammatory injuries. ”

These findings and others previously shown to demonstrate the efficacy of gelsolin in models of cytokine inflammation and storm support the development of this technology platform in both acute and chronic diseases and are currently being conducted in a study in patients with COVID-19.

Susan Levinson, PhD, CEO of BioAegis Therapeutics said, “Every time we expand studies with plasma gelsolin, we become even more confident in its potential to respond to serious medical needs where current therapy fails. The multiple roles of Gelsolin in the management of the inflammatory process hold great promise for clinical care. “

Gelsolin is a key component of the body’s immune system
Gelsolin is a human protein that is abundant in healthy people. It is ‘main regulator of inflammation’.

Compensating for depleted systemic levels of gelsolin has enormous potential to prevent debilitating and potentially fatal wound inflammation, without compromising its essential function in fighting infection and promoting repair. Its unique features are:

  • It controls excess inflammation without suppressing the immune response to threats.
  • On a host basis, it is not specific for pathogens.
  • Naturally occurring human protein.

About BioAegis
BioAegis Therapeutics Inc. is a clinical phase based in New Jersey, a private company whose mission is to utilize a key component of the body’s innate immune system, gelsolin, to prevent negative outcomes in diseases caused by inflammation and infection.

BioAegis has an exclusive license for extensive intellectual property worldwide through Harvard-Brigham and Women’s Hospital. It contains over 40 patents published to cover infections, inflammatory diseases, renal failure, multiple sclerosis and other neurological diseases. BioAegis has American biological exclusivity and recently submitted a new IP.

Investor inquiries:
Steven Cordovano
[email protected]

Media inquiries:
Christine Lagana
[email protected]

This press release contains explicit or implied forward-looking statements based on current management expectations. These statements relate, among other things, to our expectations regarding management plans, goals, and strategies. These statements are neither promises nor warranties, but are subject to a variety of risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from those envisaged in these forward-looking statements. BioAegis undertakes no obligation to update any future statements that appear in this press release in the event of a change of circumstances or otherwise, and such statements are only valid on the date they are made.